Pacira BioSciences 3Q 2026: Revenue $176.65M, EPS $0.7 — 10-Q Summary

Pacira BioSciences reported Q3 2026 revenue of $176.65M, down 2% YoY, but net income rose to $28.52M, up 425%. EXPAREL and ZILRETTA sales increased, while iovera° sales declined. Earnings benefited from gains related to contingent consideration and divestiture. Gross margin fell to 79% from 81%.

Original reporting
Published Nov 5, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pacira BioSciences 3Q 2026: Revenue $176.65M, EPS $0.7 — 10-Q Summary — source image
Decision brief

The 30-second read

$PCRXBullishMed
01

Why it matters

The earnings beat may attract short‑term buying pressure, but investors should watch for sustainability of profit drivers.

02

Market read

Earnings surprise provides a trading opportunity for PCRX and potentially influences peer biotech stocks.

03

What to watch

One-time contingent consideration and divestiture gains may not be repeatable.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

Pacira BioSciences filed its Q3 2026 10‑Q, highlighting modest revenue decline, strong profit growth, and progress on its PCRX‑201 pipeline.

Company-level read

Ticker impact

$PCRXBullishHigh confidence
Context

Q3 2026 results show revenue down 1.6% YoY but net income up 425% and EPS $0.7 versus $0.124 last year.

Expected impact

likely upward as market prices in the earnings beat and contingent gains.

Evidence & confidence

Revenue decline is modest while net income and EPS dramatically exceed prior-year levels, indicating strong profitability.

Market effects

Pain management sector may see renewed interest due to strong earnings from a key player.

U.S. biotech investors could adjust positions in small-cap pharma stocks.

Limited to investors tracking U.S. biotech earnings.

Counterpoint

Revenue decline could signal slowing demand for core products, warranting caution.

Key entities

  • Pacira BioSciences

    U.S. biotech firm reporting Q3 2026 results.

Related articles

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.

$PCRXLow

Pacira BioSciences, Inc. (PCRX): RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low